Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.
暂无分享,去创建一个
[1] A Sette,et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.
[2] S. Rosenberg,et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.
[3] S. Rosenberg,et al. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[4] M. Salgaller,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. , 1995, Cancer research.
[5] C. Farina,et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[6] K. Sakaguchi,et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. , 1995, Journal of immunology.
[7] S. Rosenberg,et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.
[8] W. Kast,et al. Induction and characterization of cytotoxic T‐lymphocytes recognizing a mutated p21ras peptide presented by HLA‐A*0201 , 1995, International journal of cancer.
[9] S. Rosenberg,et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.
[10] R. Anderson,et al. Antigen processing in vivo and the elicitation of primary CTL responses. , 1995, Journal of immunology.
[11] S. Rosenberg,et al. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. , 1995, Journal of immunology.
[12] M. Ressing,et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. , 1995, Journal of immunology.
[13] A. Sette,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.
[14] S. Rosenberg,et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. , 1995, Cancer research.
[15] A Sette,et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. , 1995, Journal of immunology.
[16] S. Rosenberg,et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. , 1995, Cancer research.
[17] R. Brasseur,et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. , 1995, Immunity.
[18] P. Kourilsky,et al. Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic , 1995, The Journal of experimental medicine.
[19] S. Rosenberg,et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261] , 1995, The Journal of experimental medicine.
[20] M. Lotze,et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.
[21] Andrew Brooks,et al. Peptide binding to MHC class I molecules: Implications for antigenic peptide prediction , 1995, Immunologic research.
[22] K. Heeg,et al. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. , 1995, Vaccine.
[23] A. Vitiello,et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.
[24] P. Coulie,et al. A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 , 1994, European journal of immunology.
[25] S. Rosenberg,et al. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. , 1994, Cancer research.
[26] D. Margulies,et al. Determinant selection of major histocompatibility complex class I- restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues , 1994, The Journal of experimental medicine.
[27] C. Figdor,et al. Molecular characterization of the melanocyte lineage-specific antigen gp100. , 1994, The Journal of biological chemistry.
[28] S. Rosenberg,et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.
[29] E. Sercarz,et al. Can antitumor immune responses discriminate between self and nonself? , 1994, Immunology today.
[30] J. Sidney,et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.
[31] F. Marincola,et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. , 1994, Journal of immunology.
[32] S. Rosenberg,et al. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. , 1994, Cancer research.
[33] S. Orlow,et al. Identification of a melanosomal matrix protein encoded by the murine si (silver) locus using "organelle scanning". , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[34] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[35] K. Sakaguchi,et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[36] J. Renauld,et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.
[37] A. Houghton. Cancer antigens: immune recognition of self and altered self , 1994, The Journal of experimental medicine.
[38] S. Rosenberg,et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. , 1994, Cancer research.
[39] D. Pardoll. A new look for the 1990s , 1994, Nature.
[40] H. Rammensee,et al. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA‐A2.1 , 1994, International journal of cancer.
[41] R. Henderson,et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.
[42] S. Rosenberg,et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[43] H. Eisen,et al. T-cell antigens in cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[44] A Sette,et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.
[45] A Sette,et al. Definition of specific peptide motifs for four major HLA-A alleles. , 1994, Journal of immunology.
[46] S. Rosenberg,et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[47] S. Steinberg,et al. Localization of 111Indium‐labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response , 1994, Cancer.
[48] H. Grey,et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[49] B. Seliger,et al. Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.
[50] J. Berzofsky,et al. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. , 1994, Cancer research.
[51] C. Figdor,et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[52] J. Schlom,et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. , 1994, Cancer research.
[53] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[54] D. Hunt,et al. Direct analysis of tumor-associated peptide antigens. , 1994, Current opinion in immunology.
[55] C. Figdor,et al. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. , 1993, The American journal of pathology.
[56] F. Marincola,et al. Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[57] J. Sidney,et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.
[58] S. H. van der Burg,et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.
[59] S. Rosenberg,et al. T-cell recognition of human melanoma antigens. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[60] S. H. van der Burg,et al. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[61] J. Yewdell,et al. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. , 1993, Journal of immunology.
[62] P. Coulie,et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.
[63] T. D. Duane,et al. Duane's Clinical Ophthalmology , 1993 .
[64] M. Herlyn,et al. Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients , 1993, The Journal of experimental medicine.
[65] S. Orlow,et al. Lysosome-associated membrane protein-1 (LAMP-1) is the melanocyte vesicular membrane glycoprotein band II. , 1993, The Journal of investigative dermatology.
[66] M. Mamula. The inability to process a self-peptide allows autoreactive T cells to escape tolerance , 1993, The Journal of experimental medicine.
[67] S. Rosenberg,et al. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[68] E. Sercarz,et al. Processing of self-proteins and its impact on shaping the T cell repertoire, autoimmunity and immune regulation. , 1993, International reviews of immunology.
[69] A. Miller,et al. Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.
[70] G. Wistow,et al. The cDNA RPE1 and monoclonal antibody HMB-50 define gene products preferentially expressed in retinal pigment epithelium. , 1992, Experimental eye research.
[71] J. Richards,et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] S. Ohno. How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[73] D. Tang,et al. Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.
[74] R. Henderson,et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.
[75] S. Rosenberg,et al. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. , 1992, Journal of immunology.
[76] T. Boon. Toward a genetic analysis of tumor rejection antigens. , 1992, Advances in cancer research.
[77] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[78] D. Barton,et al. A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[79] Samuel Hellman,et al. Important advances in oncology , 1991 .
[80] S. Rosenberg,et al. Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[81] E. Sercarz,et al. The dominant self and the cryptic self: shaping the autoreactive T-cell repertoire. , 1991, Immunology today.
[82] H. Rammensee,et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.
[83] S. Rosenberg,et al. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. , 1991, Journal of immunology.
[84] H. Seigler,et al. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. , 1991, Journal of immunology.
[85] K. Agata,et al. Complete sequence and expression of a cDNA encoding a chicken 115-kDa melanosomal matrix protein. , 1991, Pigment cell research.
[86] S. Rosenberg,et al. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. , 1990, Journal of immunology.
[87] H. Rammensee,et al. Limit of T cell tolerance to self proteins by peptide presentation. , 1990, Science.
[88] L. Steinman,et al. The T lymphocyte in experimental allergic encephalomyelitis. , 1990, Annual review of immunology.
[89] S. Rosenberg,et al. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. , 1989, Cancer research.
[90] S. Rosenberg,et al. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.
[91] C. Slingluff,et al. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. , 1989, Journal of immunology.
[92] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[93] R. Esclamado,et al. Identification of a secreted Mr 95,000 glycoprotein in human melanocytes and melanomas by a melanocyte specific monoclonal antibody. , 1988, Cancer research.
[94] D. Ruiter,et al. A monoclonal antibody specific for cells of the melanocyte lineage. , 1988, The American journal of pathology.
[95] A. Kopf,et al. Prognostic significance of hypopigmentation in malignant melanoma. , 1987, Archives of dermatology.
[96] A. Gown,et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. , 1986, The American journal of pathology.
[97] J. Kirkwood,et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. , 1983, Journal of the American Academy of Dermatology.